Duloxetine for AI-associated joint pain in breast cancer patients

Aromatase inhibitors (AIs) are the standard of care for treatment of both early and advanced hormone-sensitive breast cancer in postmenopausal women. Although AIs have been considered to be well-tolerated, only 50 % of patients can complete the full course of the treatment, at the optimal schedule (1).